May 16, 2019
Torrent Pharmaceuticals Limited (Torrent) announced on April 18, 2019, that it’s expanding its nationwide, voluntary recall for Losartan Potassium Tablets USP and Losartan Potassium/hydrochlorothiazide tablets USP to the consumer level due to detection of trace amounts of an impurity, N-Methylnitrosobutyric acid (NMBA), found in an active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited.
The expanded recall includes an additional 36 lots of Losartan potassium Tablets USP and 68 lots of Losartan Potassium/Hydrochlorothiazide Tablets USP. Get more information on the recalled products including product names, catalog numbers, lot numbers, and expiration dates.
Because Losartan treats serious medical conditions, we’re advising our customers to continue taking their prescription and to contact their provider for further instruction.
You don’t need to write a new prescription if you opt to switch your patient to a different manufacturer. For questions about potential impacts to your Premera patients, email our Physician and Provider Relations team.